| Zacks Company Profile for Cytokinetics, Incorporated (CYTK : NSDQ) |
|
|
| |
| • Company Description |
| Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Number of Employees: 498 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $36.59 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,346,831 shares |
| Shares Outstanding: 119.43 (millions) |
| Market Capitalization: $4,369.85 (millions) |
| Beta: 0.59 |
| 52 Week High: $61.38 |
| 52 Week Low: $29.31 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
10.21% |
6.08% |
| 12 Week |
-7.32% |
-22.04% |
| Year To Date |
-22.22% |
-27.16% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Robert I. Blum - President; Chief Executive Officer and Director
John T. Henderson - Chairman
Sung H. Lee - Executive Vice President; Chief Financial Officer
Robert E. Landry - Director
B. Lynne Parshall - Director
|
|
Peer Information
Cytokinetics, Incorporated (CORR.)
Cytokinetics, Incorporated (RSPI)
Cytokinetics, Incorporated (CGXP)
Cytokinetics, Incorporated (BGEN)
Cytokinetics, Incorporated (GTBP)
Cytokinetics, Incorporated (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23282W605
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 119.43
Most Recent Split Date: 6.00 (0.17:1)
Beta: 0.59
Market Capitalization: $4,369.85 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.34 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-5.32 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 12.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 22.27% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
